Other more effective approaches emerged in the past few years, such as tyrosine kinase inhibitors (TKIs) targeting angiogenesis (e.g. Sorafenib, lenvatinib, regorafenib) [3], clinically tested selective Cyclin dependent kinase 5 and 4/6 (Cdk5, Cdk4/6) inhibitors (Dinaciclib & Palbociclib) [4–6], and highly selective fibroblast growth factor receptor 4 (FGFR4) inhibitor H3B-6527 [7, 8], which pre-clinically and clinically show encouraging efficacy and have been rigorously pursued for advanced HCC. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.